Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-02

Clinical Trial Update: A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 cardiac safety study of evofosfamide (TH-302) in patients with advanced solid tumors; the current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evofosfamide (evofosfamide)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: UNKNOWN